GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (SHSE:688505) » Definitions » Change In Receivables

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Change In Receivables : ¥0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Change In Receivables?

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's change in receivables for the quarter that ended in Mar. 2024 was ¥0.0 Mil. It means Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's change in receivables for the fiscal year that ended in Dec. 2023 was ¥-10.5 Mil. It means Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Accounts Receivable increased by ¥10.5 Mil from Dec. 2022 to Dec. 2023 .

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Accounts Receivable for the quarter that ended in Mar. 2024 was ¥452.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 279.35.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's liquidation value for the three months ended in Mar. 2024 was ¥1,131.4 Mil.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Change In Receivables Historical Data

The historical data trend for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Change In Receivables Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -122.90 -83.54 -95.37 -89.73 -10.48

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (SHSE:688505) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=452.006/147.647*91
=279.35

2. In Ben Graham's calculation of liquidation value, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's accounts receivable are only considered to be worth 75% of book value:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=1233.394-464.492+0.75 * 452.006+0.5 * 46.92
=1,131.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Business Description

Traded in Other Exchanges
Address
No. 308, Cai Lun Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai, CHN, 201210
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Executives
Zhang Wen Bo Core technical personnel
Jiang Jian Ping Core technical personnel
Tao Ji Ning Core technical personnel
Shen Yi Jun Core technical personnel
Li Jun senior management
Xue Yan senior management
Wang Luo Chun Supervisors, core technical personnel
Su Yong Directors, senior managers
Zhao Da Jun Directors, senior managers
Yang Xiao Lin senior management
Gan Yi Min Senior management, core technical personnel
Yu Dai Qing Supervisors

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (SHSE:688505) Headlines

No Headlines